<code id='0EB2D2C055'></code><style id='0EB2D2C055'></style>
    • <acronym id='0EB2D2C055'></acronym>
      <center id='0EB2D2C055'><center id='0EB2D2C055'><tfoot id='0EB2D2C055'></tfoot></center><abbr id='0EB2D2C055'><dir id='0EB2D2C055'><tfoot id='0EB2D2C055'></tfoot><noframes id='0EB2D2C055'>

    • <optgroup id='0EB2D2C055'><strike id='0EB2D2C055'><sup id='0EB2D2C055'></sup></strike><code id='0EB2D2C055'></code></optgroup>
        1. <b id='0EB2D2C055'><label id='0EB2D2C055'><select id='0EB2D2C055'><dt id='0EB2D2C055'><span id='0EB2D2C055'></span></dt></select></label></b><u id='0EB2D2C055'></u>
          <i id='0EB2D2C055'><strike id='0EB2D2C055'><tt id='0EB2D2C055'><pre id='0EB2D2C055'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:33231
          hazy pages of aetna.com layered next to each other, as shown through a kaleidoscopic glass
          Adobe

          CVS Health is preparing to make significant changes to its 2025 Medicare Advantage plans, which could potentially drive away 10% of its membership, the company’s chief financial officer said at an investment banking conference Tuesday.

          “The goal for next year is margin over membership,” CVS CFO Tom Cowhey said at the conference, hosted by Bank of America. “Could we lose up to 10% of our existing Medicare members next year? That’s entirely possible. And that’s OK, because we need to get this business back on track.”

          advertisement

          CVS, through its Aetna subsidiary, is the third-largest Medicare Advantage insurer, with more than 4.2 million enrollees as of April, according to the latest federal data. That means next year CVS could push out up to 420,000 older adults and people with disabilities on its Medicare Advantage plans, forcing them to choose another plan.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Here’s what’s in the FDA plan to include pregnant women in clinical trials
          Here’s what’s in the FDA plan to include pregnant women in clinical trials

          AdobeTheFDAhastakenabigstepinencouragingdrugcompaniestoincludepregnantwomeninclinicaltrials,issuinga

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Industry veterans launch new biotech VC with $310M

          AdobeThreebiotechVCveterans,includingoneoftheco-foundersofradiopharmasuccessstoryRayzeBio,arelaunchi